ReviewKidney & blood pressure research2008
Role of aberrant glycosylation of IgA1 molecules in the pathogenesis of IgA nephropathy.
Review in Kidney & blood pressure research, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
49 citing papers in PubMed, 84 citations in OpenAlex.
- Combination therapy with or without warfarin and dipyridamole for severe childhood IgA nephropathy: an RCT.Pediatric nephrology (Berlin, Germany) · 2018Trial
- New Insights on IgA Nephropathy from the Perspective of Active Lesions and Systemic Inflammatory Responses.ImmunoTargets and therapy · 2026Review
- B Cell Activating Factor Does Not Play a Pivotal Role in the Synthesis of Aberrantly Glycosylated IgA.Nephrology (Carlton, Vic.) · 2025Article
- What is new in the pathogenesis and treatment of IgA glomerulonephritis.World journal of nephrology · 2024Review
- Bovine Colostrum in Pediatric Nutrition and Health.Nutrients · 2024Review
- Targeting altered glycosylation in secreted tumor glycoproteins for broad cancer detection.Glycobiology · 2023Article
- Identification and characterization of circulating immune complexes in IgA nephropathy.Science advances · 2022Article
- Pathogenesis of IgA Nephropathy: Current Understanding and Implications for Development of Disease-Specific Treatment.Journal of clinical medicine · 2021Review
- TLR9 activation induces aberrant IgA glycosylation via APRIL- and IL-6-mediated pathways in IgA nephropathy.Kidney international · 2020Article
- Analysis of O-glycoforms of the IgA1 hinge region by sequential deglycosylation.Scientific reports · 2020Article
- Clinical Significance of Serum Galactose-Deficient IgA1 Level in Children with IgA Nephropathy.Journal of immunology research · 2020Article
- Article
- Recent advances in the immunological understanding of association between tonsil and immunoglobulin A nephropathy as a tonsil-induced autoimmune/inflammatory syndrome.Immunity, inflammation and disease · 2019Review
- Representing glycophenotypes: semantic unification of glycobiology resources for disease discovery.Database : the journal of biological databases and curation · 2019Review
- Alteration of glycosylation in serum proteins: a new potential indicator to distinguish non-diabetic renal diseases from diabetic nephropathy.RSC advances · 2018Article
- Aberrant Glycosylation of the IgA1 Molecule in IgA Nephropathy.Seminars in nephrology · 2018Review
- Serum GDIgA1 levels in children with IgA nephropathy and Henoch-Schönlein nephritis.Central-European journal of immunology · 2018Article
- Inflammation in IgA nephropathy.Pediatric nephrology (Berlin, Germany) · 2017Review
- Monomeric Immunoglobulin A from Plasma Inhibits Human Th17 ResponsesFrontiers in immunology · 2017Article
- IgA1 Protease Treatment Reverses Mesangial Deposits and Hematuria in a Model of IgA Nephropathy.Journal of the American Society of Nephrology : JASN · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 4 institutions in 3 countries.
Funding
Abstract
Studies of the properties of immune complexes (IC) in the circulation, urine, and mesangium of IgA nephropathy (IgAN) patients have provided data relevant to the pathogenesis of this disease. IC contain predominantly polymeric IgA1 molecules which are deficient in galactose (Gal) residues on O-linked glycan chains in the hinge region (HR) of their heavy (H) chains. As a result of this aberrancy, a novel antigenic determinant(s) involving N-acetylgalactosamine (GalNAc) and perhaps sialic acid (SA) of O-linked glycans is generated and recognized by naturally occurring GalNAc-specific antibodies. Thus, IC in IgAN consist of Gal-deficient IgA1 molecules as an antigen, and GalNAc-specific IgG and/or IgA1 as an antibody. IgG antibodies to Gal-deficient IgA1 are probably induced by cross-reactive microbial antigens; they are present at variable levels not only in humans with or without IgAN but also in many phylogenetically diverse vertebrate species. Incubation of human mesangial cells with IC from sera of IgAN patients indicated that stimulation of cellular proliferative activity was restricted to the large (>800 kDa) complexes. These findings suggest that experimental approaches that prevent the formation of large Gal-deficient IgA1-IgG IC may be applied ultimately in an immunologically mediated therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.